{
  "id": 6520906,
  "title": "Belite Bio CFO Chuang Hao-Yuan sells $12.8 million in company ADSs",
  "url": "https://urgent.news/2026/09/10/belite-bio-cfo-chuang-hao-yuan-sells-12-8-million-in-company-adss",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-10T01:45:56.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/belite-bio-cfo-chuang-haoyuan-sells-128-million-in-company-adss-93CH-4894860"
  },
  "original_language": "en",
  "account": "Chuang Hao-Yuan, CFO and Director at BELITE BIO, INC (BLTE), divested 62,395 American depositary shares, valued at roughly $12.8 million, on September 4 and September 8, 2026. The shares were purchased at a price range of $180.1597 to $198.0454 per ADS through a Rule 10b5-1 trading plan initiated in December 2025. Post the sale, Chuang retained 26,038 ADSs. BELITE BIO shares are nearing their 52-week high of $200, having surged 176% in the past year. Despite being in overbought territory, the stock appears undervalued relative to its Fair Value. BELITE BIO has filed a New Drug Application with Japan’s Ministry of Health, Labour, and Welfare for tinlarebant, aimed at treating Stargardt disease type 1 under Sakigake Designation for expedited review. This has been met with bullish sentiment, with investment firms raising their price targets for the company's stock.",
  "summary": null,
  "key_points": [
    "CFO Chuang Hao-Yuan sold $12.8M in BLTE ADSs on Sep 4 and 8, 2026",
    "Shares purchased via Rule 10b5-1 plan from Dec 2025, price $180-$198",
    "BLTE nears 52-week high of $200, up 176% in past year"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}